Outpatient Medicine Update-Pulmonology Update

Video Transcription

Video Summary

The talk reviews current asthma, COPD, and community-acquired pneumonia guidance, emphasizing evidence-based prescribing and avoiding unnecessary treatment.

<strong>Asthma:</strong> GINA guidelines favor including inhaled corticosteroids (ICS) in reliever treatment rather than relying on albuterol alone. As-needed budesonide-formoterol can suit mild asthma; maintenance-and-reliever therapy is used for more frequent symptoms. Before stepping up treatment, check inhaler technique, adherence, and environmental triggers. Treat exacerbations according to severity; moderate or severe cases generally warrant a short course of oral corticosteroids, with urgent transfer for severe presentations. Biologics can improve control and reduce exacerbations and long-term steroid use. Routine chest X-rays are not needed when an exacerbation is clear and pneumonia is not suspected.

<strong>COPD:</strong> GOLD recommends classifying patients as A, B, or E to guide initial inhaler therapy, with LABA-LAMA generally favored for symptomatic patients and ICS considered according to exacerbations, eosinophil count, and asthma history. Exacerbations are commonly treated with five days of systemic steroids; antibiotics are reserved for patients with appropriate symptoms, such as increased or purulent sputum or fever. Evidence supports shorter antibiotic courses in suitable patients. Teaching inhaler technique may reduce exacerbations; air filtration and preventive antibiotics may help selected patients.

<strong>Pneumonia:</strong> Outpatient antibiotic choice depends on comorbidities and resistance risks. Do not routinely add anaerobic coverage for suspected aspiration. Use clinical stability to guide treatment duration, and avoid extending antibiotics unnecessarily; follow-up imaging is not routinely needed if recovery is as expected. The former “healthcare-associated pneumonia” category is replaced by specific MRSA and Pseudomonas risk factors. The talk also notes that opioid use is associated with increased pneumonia risk.

Keywords

asthma

COPD

community-acquired pneumonia

GINA guidelines

GOLD recommendations

inhaled corticosteroids

budesonide-formoterol

LABA-LAMA

oral corticosteroids

antibiotic stewardship

inhaler technique

biologics

pneumonia risk factors